Search

Displaying results 4181 - 4190 of 4822 in total
  1. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.

  2. Drug

    Cediranib

    go.drugbank.com/drugs/DB04849
    Investigational

    It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

  3. Drug

    N-(carboxycarbonyl)-D-phenylalanine

    go.drugbank.com/drugs/DB08263
    Experimental

    It targets the protein hypoxia-inducible factor 1-alpha inhibitor.

  4. Drug

    Ammonium molybdate

    go.drugbank.com/drugs/DB11128
    Investigational

    It is intravenously administered as an additive to solutions for Total Parenteral Nutrition (TPN).

  5. Drug

    Dihydroxymethoxychalcone

    go.drugbank.com/drugs/DB14122
    Investigational

    Cardamonin's name comes from the fact that it can be found in cardamom spice.

  6. Drug

    JPC-3210

    go.drugbank.com/drugs/DB15609
    Experimental

    It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria

  7. Drug

    Furvina

    go.drugbank.com/drugs/DB16547
    Experimental

    It is used to treat dermatological infections.[A228063]

  8. Drug

    Pimicotinib

    go.drugbank.com/drugs/DB18972
    Investigational

    It was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]

  9. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability. … It is predicted to have low drug-drug interactions and inhibition or induction of any major human metabolizing enzymes. Seletracetam was in Phase II clinical trials under the supervision of the U.S.

  10. Drug

    Mepiprazole

    go.drugbank.com/drugs/DB09197
    Experimental

    It is a pyrazolyl-alkyl-piperazine derivative. Mepiprazole mediates a weak inhibitory action on the uptake of 5-HT on hypothalamic neurons [A7816]. … It acts as a 5-HT2A and α1-adrenergic receptor antagonist, and has also been shown to inhibit the reuptake and induce the release of serotonin, dopamine, and norepinephrine to varying extents.